Literature DB >> 15799620

Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers.

A Baeyens1, H Thierens, K Claes, B Poppe, L de Ridder, A Vral.   

Abstract

PURPOSE: The chromosomal radiosensitivity of a selected group of familial breast cancer patients carrying a mutation in BRCA1 (n=11) or BRCA2 (n=9) and a group of healthy mutation carriers (n=12) was investigated and compared to a reference group of breast cancer patients without a BRCA1/2 mutation (n=78) and a group of healthy women carrying no mutation (n=58).
MATERIALS AND METHODS: The chromosomal radiosensitivity was assessed with the G2 and the G0-micronucleus (MN)-assay on fresh blood samples and on Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines. For the MN-assay, lymphocytes were exposed in vitro to 3.5 Gy and 2 Gy 60Co gamma-rays at a high dose rate (HDR) or low dose rate (LDR). 70-h post-irradiation cultures were arrested and micronuclei were scored in 1000 binucleate cells. For the G2-assay lymphocytes were irradiated in vitro with a dose of 0.4 Gy 60Co gamma-rays after 71h incubation. Cultures were arrested 90 min after irradiation and chromatid breaks were scored in 50 metaphases.
RESULTS: The group of breast cancer patients with a BRCA1 or 2 mutation was on average more radiosensitive than the control group, but not different from breast cancer patients without a BRCA mutation. The radiation response of healthy BRCA1/2 carriers was not significantly different from the control group and also not different from relatives without a BRCA mutation. Comparing the radiation response in EBV cell lines derived from breast cancer patients with or without a BRCA1 mutation revealed no significant difference.
CONCLUSIONS: Our results reveal that chromosomal radiosensitivity observed in breast cancer patients heterozygous for BRCA1 or 2 mutations, could not be demonstrated in healthy BRCA1/2 mutation carriers. This suggests that mutations in BRCA1 or 2 genes are not playing a main role in chromosomal radiosensitivity, this although BRCA1 and 2 are both involved in DNA repair/signalling processes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15799620     DOI: 10.1080/09553000400017937

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  16 in total

1.  Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.

Authors:  Hiroyuki Konishi; Morassa Mohseni; Akina Tamaki; Joseph P Garay; Sarah Croessmann; Sivasundaram Karnan; Akinobu Ota; Hong Yuen Wong; Yuko Konishi; Bedri Karakas; Khola Tahir; Abde M Abukhdeir; John P Gustin; Justin Cidado; Grace M Wang; David Cosgrove; Rory Cochran; Danijela Jelovac; Michaela J Higgins; Sabrina Arena; Lauren Hawkins; Josh Lauring; Amy L Gross; Christopher M Heaphy; Yositaka Hosokawa; Edward Gabrielson; Alan K Meeker; Kala Visvanathan; Pedram Argani; Kurtis E Bachman; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

2.  Evidence that BRCA1- or BRCA2-associated cancers are not inevitable.

Authors:  Bess Levin; Denise Lech; Bernard Friedenson
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

Review 3.  Evaluating the effects of genetic variants of DNA repair genes using cytogenetic mutagen sensitivity approaches.

Authors:  Sherif Z Abdel-Rahman; Randa A El-Zein
Journal:  Biomarkers       Date:  2011-05-20       Impact factor: 2.658

4.  Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.

Authors:  David G Cox; Jacques Simard; Daniel Sinnett; Yosr Hamdi; Penny Soucy; Manon Ouimet; Laure Barjhoux; Carole Verny-Pierre; Lesley McGuffog; Sue Healey; Csilla Szabo; Mark H Greene; Phuong L Mai; Irene L Andrulis; Mads Thomassen; Anne-Marie Gerdes; Maria A Caligo; Eitan Friedman; Yael Laitman; Bella Kaufman; Shani S Paluch; Åke Borg; Per Karlsson; Marie Stenmark Askmalm; Gisela Barbany Bustinza; Katherine L Nathanson; Susan M Domchek; Timothy R Rebbeck; Javier Benítez; Ute Hamann; Matti A Rookus; Ans M W van den Ouweland; Margreet G E M Ausems; Cora M Aalfs; Christi J van Asperen; Peter Devilee; Hans J J P Gille; Susan Peock; Debra Frost; D Gareth Evans; Ros Eeles; Louise Izatt; Julian Adlard; Joan Paterson; Jacqueline Eason; Andrew K Godwin; Marie-Alice Remon; Virginie Moncoutier; Marion Gauthier-Villars; Christine Lasset; Sophie Giraud; Agnès Hardouin; Pascaline Berthet; Hagay Sobol; François Eisinger; Brigitte Bressac de Paillerets; Olivier Caron; Capucine Delnatte; David Goldgar; Alex Miron; Hilmi Ozcelik; Saundra Buys; Melissa C Southey; Mary Beth Terry; Christian F Singer; Anne-Catharina Dressler; Muy-Kheng Tea; Thomas V O Hansen; Oskar Johannsson; Marion Piedmonte; Gustavo C Rodriguez; Jack B Basil; Stephanie Blank; Amanda E Toland; Marco Montagna; Claudine Isaacs; Ignacio Blanco; Simon A Gayther; Kirsten B Moysich; Rita K Schmutzler; Barbara Wappenschmidt; Christoph Engel; Alfons Meindl; Nina Ditsch; Norbert Arnold; Dieter Niederacher; Christian Sutter; Dorothea Gadzicki; Britta Fiebig; Trinidad Caldes; Rachel Laframboise; Heli Nevanlinna; Xiaoqing Chen; Jonathan Beesley; Amanda B Spurdle; Susan L Neuhausen; Yuan C Ding; Fergus J Couch; Xianshu Wang; Paolo Peterlongo; Siranoush Manoukian; Loris Bernard; Paolo Radice; Douglas F Easton; Georgia Chenevix-Trench; Antonis C Antoniou; Dominique Stoppa-Lyonnet; Sylvie Mazoyer; Olga M Sinilnikova
Journal:  Hum Mol Genet       Date:  2011-09-02       Impact factor: 6.150

5.  Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation.

Authors:  Bhavana V Chapman; Diane Liu; Yu Shen; Oluwafikayo O Olamigoke; David S Lakomy; Angelica M Gutierrez Barrera; Shane R Stecklein; Gabriel O Sawakuchi; Scott J Bright; Isabelle Bedrosian; Jennifer K Litton; Benjamin D Smith; Wendy A Woodward; George H Perkins; Karen E Hoffman; Michael C Stauder; Eric A Strom; Banu K Arun; Simona F Shaitelman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-10-03       Impact factor: 8.013

Review 6.  Functional assays for analysis of variants of uncertain significance in BRCA2.

Authors:  Lucia Guidugli; Aura Carreira; Sandrine M Caputo; Asa Ehlen; Alvaro Galli; Alvaro N A Monteiro; Susan L Neuhausen; Thomas V O Hansen; Fergus J Couch; Maaike P G Vreeswijk
Journal:  Hum Mutat       Date:  2013-12-03       Impact factor: 4.878

7.  Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.

Authors:  Jonine L Bernstein; Duncan C Thomas; Roy E Shore; Mark Robson; John D Boice; Marilyn Stovall; Michael Andersson; Leslie Bernstein; Kathleen E Malone; Anne S Reiner; Charles F Lynch; Marinela Capanu; Susan A Smith; Lina Tellhed; Sharon N Teraoka; Colin B Begg; Jorgen H Olsen; Lene Mellemkjaer; Xiaolin Liang; Anh T Diep; Ake Borg; Patrick Concannon; Robert W Haile
Journal:  Eur J Cancer       Date:  2013-05-21       Impact factor: 9.162

Review 8.  Ovarian cancer: in search of better marker systems based on DNA repair defects.

Authors:  Dominic Varga; Miriam Deniz; Lukas Schwentner; Lisa Wiesmüller
Journal:  Int J Mol Sci       Date:  2013-01-04       Impact factor: 5.923

Review 9.  Role of micronucleus test in predicting breast cancer susceptibility: a systematic review and meta-analysis.

Authors:  F Cardinale; P Bruzzi; C Bolognesi
Journal:  Br J Cancer       Date:  2011-12-20       Impact factor: 7.640

10.  Haploinsufficiency for BRCA1 is associated with normal levels of DNA nucleotide excision repair in breast tissue and blood lymphocytes.

Authors:  Jean J Latimer; Wendy S Rubinstein; Jennifer M Johnson; Amal Kanbour-Shakir; Victor G Vogel; Stephen G Grant
Journal:  BMC Med Genet       Date:  2005-06-14       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.